Japan’s Daiichi Sankyo is looking at a reduced review time for its acute myeloid leukaemia (AML) drug quizartinib in Europe, the top prospect in its new oncology pipeline. The European Medicines ...
AstraZeneca and Daiichi Sankyo confirmed today that they have decided to voluntarily withdraw their EU marketing application for datopotamab deruxtecan (Dato-DXd) in lung cancer, based on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback